Key Updates in the Treatment of HER2-Positive Breast Cancer

Gain expert insights on current and emerging HER2-targeted therapies for patients with HER2-positive metastatic breast cancer including best practice for managing treatment-related adverse events.

Share

Program Content

Activities

Key Updates in HER2+ MBC
Key Updates in the Treatment of HER2-Positive Breast Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 11, 2020

Expires: May 10, 2021

Faculty

cover img faculity

Jeremy Force, DO

Assistant Professor
Breast Oncology Program
Division of Medical Oncology
Department of Medicine
Duke University
Durham, North Carolina

cover img faculity

Nicholas P. McAndrew, MD, MSCE

Health Sciences Clinical Instructor
Division of Hematology/Oncology
Department of Medicine
UCLA David Geffen School of Medicine
Los Angeles, California

cover img faculity

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Seagen